Jennison Associates’s Crescent Biopharma CBIO Stock Holding History

Jennison Associates’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.81M	Buy	378,507 +225,533	+147%	+$4.4M	﹤0.01%	416
2026 Q1	$2.81M	Buy	+152,974	New	+$1.76M	﹤0.01%	427
2019 Q3	–	Sell	-14,167	Closed	-$16.9M	–	659
2019 Q2	$16.9M	Sell	14,167 -68	-0.5%	-$81.3K	0.02%	378
2019 Q1	$17.7M	Buy	14,235 +14	+0.1%	+$16K	0.02%	375
2018 Q4	$13.5M	Sell	14,221 -767	-5%	-$923K	0.02%	405
2018 Q3	$21.6M	Sell	14,988 -951	-6%	-$1.44M	0.02%	388
2018 Q2	$25.7M	Buy	15,939 +263	+2%	+$452K	0.03%	363
2018 Q1	$25.4M	Sell	15,676 -202	-1%	-$420K	0.03%	358
2017 Q4	$26.7M	Sell	15,878 -24	-0.2%	-$31.7K	0.03%	360
2017 Q3	$22.2M	Sell	15,902 -35	-0.2%	-$41.1K	0.02%	393
2017 Q2	$17.8M	Buy	+15,937	New	+$13.2M	0.02%	425

Other funds holding CBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates's CBIO Position: Q2 2026 in Review

Jennison Associates increased its Crescent Biopharma (CBIO) stake by 147% in Q2 2026, buying an estimated $4.4M and bringing the position to 378,507 shares worth $6.81M. The position accounts for ﹤0.01% of the portfolio, ranked #416.

Jennison Associates first reported a position in CBIO in Q2 2017 and has held it in 11 quarters since. The position peaked at $26.7M in Q4 2017. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

Jennison Associates held 378,507 shares of Crescent Biopharma worth $6.81M as of Q2 2026.
Jennison Associates bought 225,533 Crescent Biopharma shares in Q2 2026, an estimated $4.4M.
Crescent Biopharma made up ﹤0.01% of Jennison Associates's portfolio in Q2 2026, its #416 holding.
Jennison Associates first reported a position in Crescent Biopharma in Q2 2017 and has held it in 11 quarters since.
Jennison Associates's Crescent Biopharma position peaked at $26.7M in Q4 2017.
82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.